RPE65 and Leber congenital amaurosis: Gene augmentation or replacement therapy represents a rational drug design for treating autosomal recessive RP (arRP) and has shown clinical benefit; RPE65 gene replacement (LuxturnaTM) received United States FDA approval for Leber congenital amaurosis (LCA) 2 [3,4].